Buscar en
Medicina Clínica (English Edition)
Toda la web
Inicio Medicina Clínica (English Edition) Dyslipidaemia and atherogenic risk in patients with systemic lupus erythematosus
Journal Information
Vol. 147. Issue 2.
Pages 63-66 (July 2016)
Download PDF
More article options
Vol. 147. Issue 2.
Pages 63-66 (July 2016)
Brief report
DOI: 10.1016/j.medcle.2016.03.029
Dyslipidaemia and atherogenic risk in patients with systemic lupus erythematosus
Dislipidemia y riesgo aterogénico en pacientes con lupus eritematoso sistémico
José Antonio de Jesús Batún Garridoa,
Corresponding author

Corresponding author.
, Hugo Alberto Radillo Albaa, Éufrates Hernández Núñezb, Francisco Olánb
a Residente de tercer año de Medicina Interna, Hospital Regional de Alta Especialidad Dr. Gustavo A. Rovirosa Pérez, Villahermosa , Tabasco, Mexico
b Médico Internista y Reumatólogo, Hospital Regional de Alta Especialidad Dr. Gustavo A. Rovirosa Pérez, Villahermosa, Tabasco, Mexico
Article information
Full Text
Download PDF
Tables (3)
Table 1. Distribution of dyslipidaemic and non dyslipidaemic patients according to their general characteristics.
Table 2. Lipid profile analysis of variance and general characteristics of patients with systemic lupus erythematosus.
Table 3. Multivariate analysis of the variables studied and their association with the development of dyslipidaemia.
Show moreShow less

Dyslipidaemia is a common comorbidity in patients with systemic lupus erythematosus.

Patients and methods

Fifty-one patients were included. Variables associated with the disease and the drugs used were recorded. Atherogenic risk was calculated. Chi square was used for categorical variables. ANOVA was performed and a logistic regression model to determine the association of the variables with the presence of dyslipidaemia.


A percentage of 68.6 had dyslipidaemia. A significant difference between the presence of dyslipidaemia and activity index measured by SLEDAI was found, the presence of lupus nephritis, use of prednisone ≥20mg/day, evolution of the disease <3 years. Significance between the absence of dyslipidaemia and use of hydroxychloroquine was found. SLEDAI ≥4 and the use of prednisone ≥20mg/day were independently associated with the presence of dyslipidaemia. The average of Castelli rate was 5.02, the Kannel index was 2.97 and triglyceride/HDL-C ratio was 5.24.


Patients with systemic lupus erythematosus have a high prevalence of dyslipidaemia and a high atherogenic rate, which increases cardiovascular risk significantly.

Systemic lupus erythematosus
Atherogenic index

La dislipidemia es una comorbilidad frecuente en los pacientes con lupus eritematoso sistémico.

Pacientes y métodos

Se incluyeron 51 pacientes. Se registraron variables asociadas a la enfermedad y los fármacos empleados. Se calculó el riesgo aterogénico. Se empleó la prueba de Chi cuadrado para las variables categóricas. Se realizó ANOVA y un modelo de regresión logística para determinar la asociación de las variables con la presencia de dislipidemia.


El 68,6% presentó dislipidemia. Se encontró diferencia significativa entre la presencia de dislipidemia y el índice de actividad medido por SLEDAI, la presencia de nefropatía lúpica, el uso de prednisona20mg/día, la evolución de la enfermedad<3 años y entre la ausencia de dislipidemia y el empleo de hidroxicloroquina. SLEDAI4 y el uso de prednisona20mg/día se asociaron independientemente con la presencia de dislipidemia. La media del índice de Castelli fue de 5,02, la del de Kannel fue de 2,97 y la de triglicéridos/c-HDL fue de 5,24.


Los pacientes con lupus eritematoso sistémico presentan una gran prevalencia de dislipidemia y un alto índice aterogénico, lo cual aumenta el riesgo cardiovascular.

Palabras clave:
Lupus eritematoso sistémico
Índice aterogénico


These are the options to access the full texts of the publication Medicina Clínica (English Edition)

If you already have your login data, please click here .

If you have forgotten your password you can you can recover it by clicking here and selecting the option “I have forgotten my password”
Subscribe to

Medicina Clínica (English Edition)

Comprar acceso al artículo

Comprando el artículo el PDF del mismo podrá ser descargado

Precio 19,34 €

Comprar ahora
Phone for subscriptions and reporting of errors
From Monday to Friday from 9 a.m. to 6 p.m. (GMT + 1) except for the months of July and August which will be from 9 a.m. to 3 p.m.
Calls from Spain
932 415 960
Calls from outside Spain
+34 932 415 960
Article options
es en pt

¿Es usted profesional sanitario apto para prescribir o dispensar medicamentos?

Are you a health professional able to prescribe or dispense drugs?

Você é um profissional de saúde habilitado a prescrever ou dispensar medicamentos